Remlifanserin (ACP-204) - (RADIANT)

July 20, 2026: Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) announced the FDA granted Fast Track designation to remlifanserin (ACP-204), a selective 5‑HT2A receptor inverse agonist, for treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

The company also provided a development update for RADIANT: enrollment in the Phase 2 portion has been completed, and topline results are now expected in September to October 2026. Screening and enrollment are underway for the Phase 3 studies under RADIANT’s “operationally seamless” design.